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ABSTRACT
Using pharmacokinetic ⁄pharmacodynamic principles, pharmacokinetically enhanced amoxicillin ⁄
clavulanate 2000 ⁄ 125 mg twice daily was designed to provide adequate levels of amoxicillin over the
12-h dosing interval to eradicate penicillin-resistant Streptococcus pneumoniae (PRSP, penicillin MICs
‡ 2 mg ⁄L) with amoxicillin MICs of at least 4 mg ⁄L. The clinical efﬁcacy of amoxicillin ⁄ clavulanate
2000 ⁄ 125 mg was evaluated in patients with respiratory tract infections caused by S. pneumoniae,
including isolates with elevated penicillin (2–8 mg ⁄L) MICs. Data from 10 clinical studies were
combined: seven randomised (1:1), double-blind, controlled trials (efﬁcacy intent-to-treat [ITT]
N ¼ 3376): amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg twice daily vs. levoﬂoxacin 500 mg once daily in acute
bacterial sinusitis (ABS); levoﬂoxacin 500 mg once daily in acute exacerbations of chronic bronchitis
(AECB); clarithromycin 500 mg twice daily in AECB; amoxicillin ⁄ clavulanate 875 ⁄ 125 mg twice
daily ⁄ three times daily and 1000 ⁄ 125 mg three times daily in community-acquired pneumonia (CAP)
and three noncomparative studies (efﬁcacy ITT N ¼ 3024): two in ABS, one in CAP. The bacteriological
per-protocol (PP) population at follow up (days 14–39) comprised 1295 patients for amoxicillin ⁄ clavul-
anate 2000 ⁄ 125 mg and 241 for comparators. With amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg at follow-up,
outcome was successful (clinical success and eradication ⁄presumed eradication) in 85 ⁄ 90 (94.4%)
patients with S. pneumoniae in comparative studies and 421 ⁄ 445 (94.6%) in noncomparative studies, and
with comparators 58 ⁄ 70 (82.9%) were successes. In the amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg group at
follow up, 52 ⁄ 552 S. pneumoniae isolates were resistant to penicillin. At follow up, 50 ⁄ 52 (96.2%) patients
with PRSPwere successes, including 6 ⁄ 7 with amoxicillinMICs of 4 mg ⁄L and 7 ⁄ 8 with amoxicillin MICs
of 8 mg ⁄L. Success rates for amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg against PRSP were similar for CAP
(96.0% [24 ⁄ 25]), AECB (100% [3 ⁄ 3]) and ABS (95.8% [23 ⁄ 24]). There were six PRSP isolates in the
comparator group (two isolates were from one patient), and three of ﬁve patients in this group were
successes. In conclusion, amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg demonstrated combined clinical ⁄ bac-
teriological success against 50 ⁄ 52 patients with PRSP, including 13 ⁄ 15 strains with amoxicillin MICs of
4–8 mg ⁄L. These results for the pharmacokinetic-enhanced formulation of amoxicillin ⁄ clavulanate
2000 ⁄ 125 mg are in line with the high efﬁcacy against PRSP predicted using pharmacokinetic ⁄
pharmacodynamic parameters.
Keywords Streptococcus pneumoniae, amoxicillin ⁄ clavulanate, penicillin-resistant Streptococcus pneu-
moniae, pharmacokinetics ⁄pharmacodynamics, clinical study
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INTRODUCTION
Antibacterial treatment of respiratory tract infec-
tions (RTIs) is becoming increasingly difﬁcult as
the prevalence of resistance among the key
causative pathogens increases [1]. Antimicrobial
resistance among Streptococcus pneumoniae is now
present world-wide, with many strains resistant
to multiple drugs [2].
The clinical impact of infection with drug-
resistant S. pneumoniae (DRSP) is debated. The
emergence of DRSP, however, has led to both
complications in empiric therapy for RTIs and
increased numbers of treatment failures [3,4].
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There is a need therefore for drugs that can
overcome DRSP.
Amoxicillin and amoxicillin ⁄ clavulanate are
commonly used to treat a variety of RTIs.
Although some penicillin-resistant S. pneumoniae
strains (PRSP, penicillin MICs ‡ 2 mg ⁄L) are also
resistant to amoxicillin, this resistance can be
overcome by extending the time above MIC
(T > MIC) for which amoxicillin is present in
serum [5]. In a paediatric suspension formulation
this can be achieved by simply increasing the
amoxicillin dose (see Jacobs, this issue). A high-
dose paediatric formulation of amoxicillin ⁄
clavulanate (90 ⁄ 6.4 mg ⁄ kg ⁄day) is now available
in the USA. This formulation has been demons-
trated to be effective in eradicating 98% of
S. pneumoniae isolates from children with acute
otitis media, including 22 ⁄ 24 isolates with amox-
icillin MICs of 2 mg ⁄L, 3 ⁄ 4 with amoxicillin
MICs of 4 mg ⁄L and 3 ⁄ 3 with amoxicillin MICs
of 8 mg ⁄L [6]. It is not possible to provide the
required levels of amoxicillin in a standard,
immediate-release tablet; therefore a sustained-
release approach is required to achieve the
extended target T >MIC.
A new, pharmacokinetically enhanced adult
formulation of amoxicillin ⁄ clavulanate (amoxicil-
lin ⁄ clavulanate 2000 ⁄ 125 mg) has been designed,
using pharmacokinetic ⁄pharmacodynamic prin-
ciples, to eradicate PRSP with amoxicillin MICs of
at least 4 mg ⁄L [7]. A sustained-release technol-
ogy is used to extend the time for which serum
levels of amoxicillin exceed this MIC. This new
formulation and the principles on which it was
designed are described in detail elsewhere in this
issue.
The number of resistant isolates found in any
clinical study is likely to be small; therefore a
pooled analysis provides a way to examine the
efﬁcacy of an agent against these strains. To this
end, data from 10 clinical studies were combined
to evaluate the efﬁcacy of amoxicillin ⁄ clavulanate
2000 ⁄ 125 mg against DRSP, and in particular,
PRSP.
MATERIALS AND METHODS
Seven randomised (1:1), multicentre, double-
blind, double-dummy, parallel-group trials and
three noncomparative trials were included in the
analysis. Details of indications treated, compara-
tor agents (for comparative trials) and treatment
regimens are given in Table 1.
All the studies were conducted in accordance
with Good Clinical Practice and the Declaration of
Helsinki as amended in Somerset West, Republic
of South Africa in 1996. All protocols were
approved by national, local or institution ethics
committees or review boards, as appropriate for
each centre. All patients gave written, dated,
informed consent before entering a study.
Study participants
Male and female immunocompetent adults with
acute bacterial sinusitis (ABS), acute exacerba-
tions of chronic bronchitis (AECB) or community-
acquired pneumonia (CAP) were enrolled in the
trials providing they met the inclusion criteria for
the individual study. Age and clinical require-
ments for study entry are summarised in Table 2.
In brief, all patients had to be suitable for oral
Table 1. Indication, comparator agents, treatment regimen and clinic visits of studies included in the pooled analysis
Indication Comparator
Treatment
duration
Visits
On therapy End of therapy Follow up
ABS Levoﬂoxacin 500 mg once daily 10 days days 3–5 days 11–16 days 17–28
ABS Noncomparative 10 days days 3–5 days 11–16 days 17–28
ABS Noncomparative 10 days days 3–5 days 11–16 days 17–28
AECB Levoﬂoxacin 500 mg once daily 7 days days 2–7 days 8–13 days 14–23
AECB Clarithromycin 500 mg twice daily 7 days days 2–7 days 8–13 days 14–23
CAP Amoxicillin ⁄ clavulanate 875 ⁄ 125 mg twice daily 7 days days 3–5 days 8–15 days 16–37
CAP Amoxicillin ⁄ clavulanate 875 ⁄ 125 mg twice daily 7 days days 3–5 days 8–15 days 16–37
CAP Amoxicillin ⁄ clavulanate 875 ⁄ 125 mg three times daily 7 or 10 days days 3–5 days 8–17 days 18–39
CAP Amoxicillin ⁄ clavulanate 1000 ⁄ 125 mg three times daily 10 days days 3–5 days 11–17 days 18–39
CAP Noncomparative 7 days days 2–7 days 8–15 days 16–37
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therapy and be willing and able to comply with
the study protocol. A negative urine pregnancy
test prior to study entry was required for all
female patients of child-bearing potential. Addi-
tionally, in one CAP study and two AECB studies,
an additional serum pregnancy test was per-
formed at study entry.
Patients were excluded from the studies if
they had a known hypersensitivity to any study
medication, a possible risk of drug interactions,
known or suspected renal impairment or im-
paired liver function, or any complicating infec-
tion or disease that would compromise the
efﬁcacy evaluation of the treatment. Prior treat-
ment with antimicrobials for the current infec-
tion was a reason for exclusion in ABS and
AECB studies. In CAP studies, however, patients
could have received up to 24 h of antimicrobial
therapy for the current episode and, in one
study, were included if they had failed therapy
with a macrolide or ﬁrst-generation cephalospo-
rin. Additionally, one CAP study allowed the
inclusion of patients in whom previous antimi-
crobial treatment had failed, provided they had
Gram-positive cocci present on direct examina-
tion of a respiratory sample smear. Pregnancy,
lactation and inadequate methods of birth con-
trol were all reasons for exclusion for female
patients.
In all studies, the intent-to-treat (ITT) popula-
tion consisted of all patients who received at
least one dose of study medication. In the
randomised trials, this was further deﬁned as
all patients who were randomised and received
at least one dose of study medication. The
clinical per-protocol (PP) population excluded
patients who violated the relevant study protocol
to a degree that would affect treatment out-
comes. The bacteriology ITT population was a
subset of the ITT population and included only
patients who had at least one typical pathogen
isolated at screening. The bacteriology PP pop-
ulation was a subset of the bacteriology ITT
population, and excluded those patients who
violated the relevant study protocol to a degree
that would affect treatment outcomes.
Bacteriology
Bacterial isolates were determined to be suscept-
ible, intermediateor resistant toantimicrobialsbased
on National Committee for Clinical Laboratory
Standards (NCCLS) interpretative breakpoints
[8]. NCCLS breakpoints have not yet been assigned
for amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg.
Assessment of outcome
Once enrolled, patients were expected to attend
the clinic for on-therapy (days 2–7), end-of-ther-
apy (days 8–17) and follow-up (days 14–39) visits
(Table 1).
Success, for the purposes of the pooled analy-
sis, was deﬁned as bacteriological eradication of
the infecting pathogen or clinical efﬁcacy, in the
absence of repeat evaluable cultures, in patients
with conﬁrmed bacteriological infection at screen-
ing. The efﬁcacy of amoxicillin ⁄ clavulanate
2000 ⁄ 125 mg was evaluated against strains of
S. pneumoniae that included isolates with penicil-
lin MICs £ 8 mg ⁄L.
RESULTS
Patient disposition and prevalence of PRSP
Comparative and noncomparative studies inclu-
ded 3376 and 3024 patients, respectively, in the
efﬁcacy ITT populations. A total of 1915 patients
were included in the overall bacteriology ITT
population (amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg,
1593; all comparators, 322 [Figure 1]). A total of 69
PRSP isolates were identiﬁed in the amoxicil-
lin ⁄ clavulanate 2000 ⁄ 125 mg treatment group and
10 in the comparator group (Figure 1). In the
comparative trials, the amoxicillin ⁄ clavulanate
2000 ⁄ 125 mg treatment group and the combined
comparator group were well matched for patient
demographics (Table 3). In both comparative and
noncomparative studies, the majority of patients
were white. In comparative studies, the majority
of patients were male, but there were slightly
more females than males in the noncomparative
studies.
The bacteriology PP population included 1295
patients in the amoxicillin ⁄ clavulanate 2000 ⁄ 125
mg group and 241 in the comparator group, with
52 and six PRSP isolates identiﬁed, respectively
(Fig. 1).
PRSP resistance to other antimicrobials
In the amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg treat-
ment group, 13.5% (7 ⁄ 52) of PRSP isolates were of
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intermediate resistance to amoxicillin (amoxicillin
MICs 4 mg ⁄L), and a further 15.4% (8 ⁄ 52) were
fully resistant to amoxicillin (amoxicillin MICs
8 mg ⁄L) (Fig. 2).
Erythromycin resistance (erythromycin MICs
‡ 1 mg ⁄L) was highly prevalent among PRSP in
both the amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg
group and the comparator group (67.3% and
60.0%, respectively).
Efﬁcacy of amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg
With amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg, out-
come was successful in 506 ⁄ 535 (94.6%) patients
in the bacteriology PP population with S. pneu-
moniae isolated at screening. The success rates of
amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg in patients
with S. pneumoniae in the noncomparative and
comparative studies were similar (Fig. 3).
For patients in the bacteriology PP population
with PRSP, amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg
achieved a success rate of 96.2% (50 ⁄ 52) (Fig. 4).
The efﬁcacy of amoxicillin ⁄ clavulanate 2000 ⁄
125 mg in patients with PRSP was consis-
tently high across the three indications studied
(Fig. 5), and was similar in the noncomparative
and comparative studies (95.1% [39 ⁄ 41] and 100%
[11 ⁄ 11], respectively) (Fig. 4). Success rates for
amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg against
PRSP also resistant to erythromycin were similarly
high, at 96.7% (29 ⁄ 30) in the noncomparative and
100% (5 ⁄ 5) in the comparative studies.
Of the two patients in the bacteriology PP
population with PRSP isolated at screening and
treated with amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg
who were treatment failures, one was being
treated for CAP and the other for ABS. The
patient with CAP had PRSP with an amoxicillin
MIC of 8 mg ⁄L isolated at screening. This patient
was considered a clinical failure at follow up,
requiring additional antimicrobial therapy. In the
Bacteriology ITT population
(a) Bacteriology ITT population
AMX/CA 2000/125 mg
(N = 1593)
Comparators
(N = 322)
S. pneumoniae
661 isolates from 638 patients
S. pneumoniae
96 isolates from 92 patients
PRSP
69 isolates from 67 patients
(5 from blood, CAP)
PRSP
10 isolates from 9 patients
(3 from blood, CAP)
Bacteriology PP population
(b) Bacteriology PP follow-up population
AMX/CA 2000/125 mg
(N = 1295)
Comparators
(N = 241)
S. pneumoniae
552 isolates from 535 patients
S. pneumoniae
74 isolates from 70 patients
PRSP
52 isolates from 52 patients
(3 from blood, CAP)
PRSP
6 isolates from 5 patients
(1 from blood, CAP)
Fig. 1. Distribution of patients and S. pneumoniae isolates.
(a) Bacteriology ITT population. (b) Bacteriology PP
follow-up population.
Table 3. Patient demographics, efﬁcacy ITT population
Characteristic
Comparative studies Noncomparative studies
Amoxicillin ⁄ clavulanate
2000 ⁄ 125 mg N = 1678
Comparators
N = 1698
Amoxicillin ⁄ clavulanate
2000 ⁄ 125 mg N = 3024
Race, n (%)
White 1516 (90.3) 1546 (91.0) 2217 (73.3)
Black 69 (4.1) 70 (4.1) 253 (8.4)
Oriental 27 (1.6) 21 (1.2) 249 (8.2)
Other 66 (3.9) 61 (3.6) 305 (10.1)
Gender, n (%)
Male 893 (53.2) 886 (52.2) 1471 (48.6)
Female 785 (46.8) 812 (47.8) 1553 (51.4)
Age (years)
Mean (SD) 54.4 (17.3) 53.4 (17.1) 43.8 (16.8)
Range 16–96 16–94 16–98
Percentages may not add to 100% due to rounding.
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absence of a repeat sputum sample from this
patient, the PRSP isolated at screening was pre-
sumed to have recurred. Thus, the patient was
also considered a bacteriological failure after
treatment. Further results from paired sera
revealed that the patient also had a current or
recent infection with Mycoplasma pneumoniae. The
patient treated for ABS had PRSP with an amox-
icillin MIC of 4 mg ⁄L isolated at screening. At
follow up, this patient was considered a radiolo-
gical failure and suffered a recurrence of symp-
toms. No repeat sinus puncture was performed,
however, so it was not possible to determine
whether the patient was a bacteriological failure.
Fifteen patients in the bacteriology PP popula-
tion had S. pneumoniae with amoxicillin MICs of
4 or 8 mg ⁄L. The success rate for amoxicillin ⁄
clavulanate 2000 ⁄ 125 mg was 13 ⁄ 15 (86.7%) in
these patients (Table 4).
Fifteen patients in the amoxicillin ⁄ clavulanate
2000 ⁄ 125 mg group with PRSP isolated at screen-
ing were excluded from the bacteriology PP
group. Clinical success rates at follow up for
these patients were 100% (3 ⁄ 3) for ABS, 63.6%
0 20
Susceptible Intermediate Resistant
40 60 80 100
Percentage of PRSP
71.1 13.5 15.4
Fig. 2. Amoxicillin susceptibility (susceptible £ 2 mg ⁄L,
intermediate 4 mg ⁄L, resistant ‡ 8 mg ⁄L) of PRSP isolated
in the bacteriology PP population at follow up (N ¼ 52)
from the amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg treatment
group.
20
0
40
60
80
100
Su
cc
es
s (%
)
Noncomparative
studies
Comparative
studies
Amoxicillin/clavulanate 2000/125 mg
Comparators
94.6
(421/445)
94.4
(85/90)
82.9
(58/70)
Fig. 3. Efﬁcacy of amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg in
patients with S. pneumoniae vs. comparators (bacteriology
PP population at follow up).
20
0
40
60
80
100
Su
cc
es
s (%
)
CAP AECB
Indication
ABS
96.0
(24/25)
100
(3/3) 95.8
(23/24)
Fig. 5. Efﬁcacy of amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg in
patients with PRSP, by indication (bacteriology PP popu-
lation at follow up).
20
0
40
60
80
100
Su
cc
es
s (%
)
All PRSP Noncomparative
studies
Comparative
studies
96.2
(50/52) 95.1(39/41)
100
(11/11)
Fig. 4. Efﬁcacy of amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg in
patients with PRSP (bacteriology PP population at follow
up).
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(7 ⁄ 11) for CAP and 100% (1 ⁄ 1) for AECB. Of the
four failures, one patient did not attend either the
end-of-therapy or follow-up visits and was given
an outcome of ‘unable to determine’ and a second
patient was a success at end of therapy, but was
lost to follow up and given an outcome of ‘unable
to determine’ at this visit. The third CAP failure
had a penicillin- and macrolide-resistant S. pneu-
moniae isolated from blood at screening (MICs 2
and > 32 mg ⁄L, respectively), but was withdrawn
from therapy after 5 days because of insufﬁcient
therapeutic effect and deemed a failure at end of
therapy and follow up. The ﬁnal CAP failure had
a penicillin-, amoxicillin ⁄ clavulanic acid- and
macrolide-resistant S. pneumoniae (MICs 16,
16, > 32 mg ⁄L, respectively) isolated at screening
as well as positive serology for M. pneumoniae.
This patient was a success at end of therapy but
was lost to follow up and given an outcome of
‘unable to determine’ for this visit.
Efﬁcacy of comparators
The efﬁcacy of all comparators combined against
S. pneumoniae was 82.9% (58 ⁄ 70) (Fig. 3). In
patients with PRSP isolated at screening, the
success rate for all comparators combined was
60.0% (3 ⁄ 5 patients; per isolate the efﬁcacy was
4 ⁄ 6 successes). Of the two patients who failed
therapy, one was diagnosed with CAP and had a
penicillin- and macrolide-resistant S. pneumoniae
isolated at screening (MICs 2 and > 32 mg ⁄L,
respectively). This patient received amoxicil-
lin ⁄ clavulanate 1000 ⁄ 125 mg three times daily
and was a failure at end of therapy and follow
up. The second patient received clarithromycin
for CAP, had a penicillin- and macrolide-resistant
S. pneumoniae isolated at screening (MICs both
2 mg ⁄L) and was a successful outcome at end of
therapy, but a failure at follow up. For PRSP that
were also erythromycin resistant, the combined
success rate for the comparators was 66.7% (2 ⁄ 3
patients; per isolate efﬁcacy was also 2 ⁄ 3).
Four patients in the comparator group with
PRSP isolated at screening were excluded from
the bacteriology PP group, three with CAP and
one with AECB. All of these patients were
clinical failures. The three CAP failures all
received amoxicillin ⁄ clavulanate comparator for-
mulations. One patient, who received amoxicil-
lin ⁄ clavulanate 875 ⁄ 125 mg twice daily, had two
pathogens isolated at screening; a PRSP (MIC
2 mg ⁄L) and a b-lactamase-positive methicillin-
susceptible Staphylococcus aureus. This patient did
not attend any further visits and so was given an
outcome of ‘unable to determine’. The second
CAP patient received amoxicillin ⁄ clavulanate
875 ⁄ 125 three times daily, and had a penicillin-
and macrolide-resistant S. pneumoniae isolated
from blood at screening (MICs 4 and > 32 mg ⁄L,
respectively; amoxicillin ⁄ clavulanic acid MIC
2 mg ⁄L). This patient, who was HIV-positive,
was withdrawn due to a serious adverse event of
treatment failure (unrelated to the study medi-
cation) and so was a failure at end of therapy
and follow up. The third CAP patient received
amoxicillin ⁄ clavulanate 1000 ⁄ 125 mg three times
daily, had PRSP isolated from blood at screen-
ing, and was withdrawn after 2 days due to an
adverse event of delirium (unrelated to study
medication), giving an outcome of ‘unable to
determine’ for the end-of-therapy and follow-up
visits. The patient with AECB received levoﬂ-
oxacin 500 mg once daily, had a penicillin- and
macrolide-resistant S. pneumoniae (MICs 2 and
> 32 mg ⁄L, respectively) and two isolates of
Klebsiella pneumoniae at screening, and was with-
drawn after 6 days due to an adverse event of
dizziness, giving an outcome of ‘unable to
determine’ for both study visits.
CONCLUSIONS
In this pooled efﬁcacy analysis of 10 clinical
studies of pharmacokinetically enhanced amoxi-
cillin ⁄ clavulanate 2000 ⁄ 125 mg, the new formula-
tion demonstrated high efﬁcacy in patients with
RTIs due to S. pneumoniae, including DRSP. In
patients who were considered treatment failures,
Table 4. Success rates for amoxicillin ⁄ clavulanate
2000 ⁄ 125 mg against isolates of S. pneumoniae, by
amoxicillin ⁄ clavulanic acid MIC, in the bacteriology PP
population
Amoxicillin ⁄ clavulanate
MIC (mg ⁄L)
Number of isolates
(N = 550)a
Success
N (%)
£ 0.015–0.25 482 456 (94.6)
0.5 7 6 (85.7)
1 15 13 (86.7)
2 31 31 (100)
4 7 6 (85.7)
8 8 7 (87.5)
aTwo patients each had one S. pneumoniae pathogen for
which the amoxicillin MIC was unknown.
34 Clinical Microbiology and Infection, Volume 10 Supplement 2, 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10 (Suppl. 2), 28–35
repeat cultures were not performed, making it
impossible to assess whether these patients were
true bacteriological failures following treatment
with amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg, or
whether their clinical symptoms and, in the case
of the ABS patient, radiological symptoms, were
due to a secondary cause. In both cases, the initial
infecting pathogen was nonsusceptible to amox-
icillin at current NCCLS breakpoints.
The prevalence of PRSP in this combined
analysis is in line with rates found in surveillance
studies [2,9]. The prevalence of PRSP also resist-
ant to erythromycin was also in line with the
range of values reported in a recent world-wide
study [2]. The presence of resistance to penicillin
or penicillin plus erythromycin did not appear to
impair the efﬁcacy of amoxicillin ⁄ clavulanate
2000 ⁄ 125 mg, which achieved 96.2% and 97.1%
success against these pathogens, respectively.
The high rates of success seen with amoxicil-
lin ⁄ clavulanate 2000 ⁄ 125 mg are in line with
those predicted using pharmacokinetic ⁄pharmaco-
dynamic parameters. In both in-vitro and animal
studies, this sustained-release formulation (simu-
lating human pharmacokinetics) demonstrated
high bactericidal activity [10,11]. Bacterial eradica-
tion in RTIs is associated with both improved
clinical outcome and may also reduce the devel-
opment and spread of resistant pathogens [12].
Treatment with this new amoxicillin ⁄ clavula-
nate formulation may provide beneﬁts in addition
to high rates of clinical cure. Recent evidence
indicates that a high dose and short duration
(5 days) of treatment with amoxicillin is followed
by less carriage of resistant pneumococci in the
nasopharynx [13]. The nasopharynx serves as a
reservoir for re-infection of the respiratory tract
[12,14]. It is therefore likely that eradication of
pneumococci, particularly PRSP, from the naso-
pharynx may reduce the risk of treatment failure
or recurrent illness.
As the prevalence of DRSP, including multi-
drug-resistant strains, continues to increase
world-wide, conventional therapies, among
them conventional formulations of amoxicil-
lin ⁄ clavulanate, will become less reliable in the
clinical setting. In many countries, the condi-
tions already exist in which the pharmacokinet-
ically enhanced formulation of amoxicillin ⁄
clavulanate 2000 ⁄ 125 mg twice daily may be
considered appropriate for ﬁrst-line empiric
therapy in RTIs.
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